0 11 Leukotriene Leukotriene NNP 12 14 B4 B4 NNP 15 25 stimulates stimulate VBZ 26 31 c-fos c-fos NN 32 35 and and CC 36 41 c-jun c-jun NN 42 46 gene gene NN 47 60 transcription transcription NN 61 64 and and CC 65 69 AP-1 ap-1 NN 70 77 binding binding NN 78 86 activity activity NN 87 89 in in IN 90 95 human human JJ 96 105 monocytes monocyte NNS 105 106 . . . 108 110 We we PRP 111 115 have have VBP 116 124 examined examine VBN 125 128 the the DT 129 135 effect effect NN 136 138 of of IN 139 150 leukotriene leukotriene NN 151 153 B4 b4 NN 154 155 ( ( ( 155 159 LTB4 LTB4 NNP 159 160 ) ) ) 160 161 , , , 162 163 a a DT 164 170 potent potent JJ 171 176 lipid lipid NN 177 192 proinflammatory proinflammatory JJ 193 201 mediator mediator NN 201 202 , , , 203 205 on on IN 206 209 the the DT 210 220 expression expression NN 221 223 of of IN 224 227 the the DT 228 243 proto-oncogenes proto-oncogene NNS 244 249 c-jun c-jun NN 250 253 and and CC 254 259 c-fos c-fos NN 259 260 . . . 261 263 In in IN 264 272 addition addition NN 272 273 , , , 274 276 we we PRP 277 283 looked look VBD 284 286 at at IN 287 290 the the DT 291 301 modulation modulation NN 302 304 of of IN 305 312 nuclear nuclear JJ 313 320 factors factor NNS 321 328 binding bind VBG 329 341 specifically specifically RB 342 344 to to TO 345 348 the the DT 349 353 AP-1 ap-1 NN 354 361 element element NN 362 367 after after IN 368 372 LTB4 ltb4 NN 373 384 stimulation stimulation NN 384 385 . . . 386 390 LTB4 LTB4 NNP 391 400 increased increase VBD 401 404 the the DT 405 415 expression expression NN 416 418 of of IN 419 422 the the DT 423 428 c-fos c-fos NN 429 433 gene gene NN 434 436 in in IN 437 438 a a DT 439 444 time- time- NN 445 448 and and CC 449 472 concentration-dependent concentration-dependent JJ 473 479 manner manner NN 479 480 . . . 481 484 The the DT 485 490 c-jun c-jun NN 491 495 mRNA mRNA NNP 495 496 , , , 497 502 which which WDT 503 505 is be VBZ 506 520 constitutively constitutively RB 521 530 expressed express VBN 531 533 in in IN 534 539 human human JJ 540 556 peripheral-blood peripheral-blood JJ 557 566 monocytes monocyte NNS 567 569 at at IN 570 580 relatively relatively RB 581 585 high high JJ 586 592 levels level NNS 592 593 , , , 594 597 was be VBD 598 602 also also RB 603 611 slightly slightly RB 612 621 augmented augment VBN 622 624 by by IN 625 629 LTB4 ltb4 NN 629 630 , , , 631 639 although although IN 640 642 to to TO 643 644 a a DT 645 649 much much RB 650 655 lower low JJR 656 662 extent extent NN 663 667 than than IN 668 673 c-fos c-fos NN 673 674 . . . 675 678 The the DT 679 687 kinetics kinetic NNS 688 690 of of IN 691 701 expression expression NN 702 704 of of IN 705 708 the the DT 709 712 two two CD 713 718 genes gene NNS 719 723 were be VBD 724 728 also also RB 729 737 slightly slightly RB 738 747 different different JJ 747 748 , , , 749 753 with with IN 754 759 c-fos c-fos NN 760 764 mRNA mrna NN 765 773 reaching reach VBG 774 775 a a DT 776 780 peak peak NN 781 783 at at IN 784 786 15 15 CD 787 790 min min NN 791 796 after after IN 797 808 stimulation stimulation NN 809 812 and and CC 813 818 c-jun c-jun NN 819 821 at at IN 822 824 30 30 CD 825 828 min min NN 828 829 . . . 830 834 Both both DT 835 843 messages message NNS 844 851 rapidly rapidly RB 852 860 declined decline VBD 861 871 thereafter thereafter RB 871 872 . . . 873 882 Stability stability NN 883 885 of of IN 886 889 the the DT 890 895 c-fos c-fos NN 896 899 and and CC 900 905 c-jun c-jun NN 906 910 mRNA mrna NN 911 914 was be VBD 915 918 not not RB 919 927 affected affect VBN 928 930 by by IN 931 935 LTB4 ltb4 NN 935 936 , , , 937 939 as as IN 940 948 assessed assess VBN 949 954 after after IN 955 966 actinomycin actinomycin NN 967 968 D D NNP 969 978 treatment treatment NN 978 979 . . . 980 987 Nuclear nuclear JJ 988 1001 transcription transcription NN 1002 1009 studies study NNS 1010 1012 in in FW 1013 1018 vitro vitro FW 1019 1025 showed show VBD 1026 1030 that that IN 1031 1035 LTB4 ltb4 NN 1036 1045 increased increase VBD 1046 1049 the the DT 1050 1063 transcription transcription NN 1064 1066 of of IN 1067 1070 the the DT 1071 1076 c-fos c-fos NN 1077 1081 gene gene NN 1082 1088 7-fold 7-fold RB 1089 1092 and and CC 1093 1096 the the DT 1097 1102 c-jun c-jun NN 1103 1107 gene gene NN 1108 1116 1.4-fold 1.4-fold RB 1116 1117 . . . 1118 1125 Resting rest VBG 1126 1135 monocytes monocyte NNS 1136 1145 contained contain VBD 1146 1153 nuclear nuclear JJ 1154 1161 factors factor NNS 1162 1169 binding bind VBG 1170 1172 to to TO 1173 1176 the the DT 1177 1181 AP-1 ap-1 NN 1182 1189 element element NN 1189 1190 , , , 1191 1194 but but CC 1195 1206 stimulation stimulation NN 1207 1209 of of IN 1210 1219 monocytes monocyte NNS 1220 1224 with with IN 1225 1229 LTB4 ltb4 NN 1230 1237 induced induce VBD 1238 1245 greater great JJR 1246 1258 AP-1-binding ap-1-binding JJ 1259 1267 activity activity NN 1268 1270 of of IN 1271 1278 nuclear nuclear JJ 1279 1287 proteins protein NNS 1287 1288 . . . 1289 1294 These these DT 1295 1302 results result NNS 1303 1311 indicate indicate VBP 1312 1316 that that IN 1317 1321 LTB4 ltb4 NN 1322 1325 may may MD 1326 1334 regulate regulate VB 1335 1338 the the DT 1339 1349 production production NN 1350 1352 of of IN 1353 1362 different different JJ 1363 1372 cytokines cytokine NNS 1373 1375 by by IN 1376 1386 modulating modulate VBG 1387 1390 the the DT 1391 1396 yield yield NN 1397 1403 and/or and/or CC 1404 1407 the the DT 1408 1416 function function NN 1417 1419 of of IN 1420 1433 transcription transcription NN 1434 1441 factors factor NNS 1442 1446 such such JJ 1447 1449 as as IN 1450 1462 AP-1-binding ap-1-binding JJ 1463 1477 proto-oncogene proto-oncogene NN 1478 1486 products product NNS 1486 1487 . . .